VYNE Therapeutics Says US FDA Clears Its Investigational New Drug Application for Potential Autoimmune Treatment
VYNE Therapeutics Says US FDA Clears Its Investigational New Drug Application for Potential Autoimmune Treatment
VYNE Therapeutics表示，美國食品藥品管理局批准了其潛在自身免疫治療的研究性新藥申請
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊